About InDex Pharmaceuticals
InDex Pharmaceuticals is a company based in Stockholm (Sweden) founded in 2000.. InDex Pharmaceuticals has raised $45.42 million across 6 funding rounds from investors including SEB, Vinnova and NeoMed. InDex Pharmaceuticals offers products and services including Investment Services and Insights Platform. InDex Pharmaceuticals operates in a competitive market with competitors including BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others.
- Headquarter Stockholm, Sweden
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Flerie Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45.42 M (USD)
in 6 rounds
-
Latest Funding Round
$14.12 M (USD), Private Equity Round
Sep 01, 2019
-
Investors
SEB
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InDex Pharmaceuticals
InDex Pharmaceuticals offers a comprehensive portfolio of products and services, including Investment Services and Insights Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides funding and support for biotech startups
Offers updates on pharmaceutical advancements and portfolio news
Unlock access to complete
Unlock access to complete
Funding Insights of InDex Pharmaceuticals
InDex Pharmaceuticals has successfully raised a total of $45.42M across 6 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $14.12 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Private Equity Round — $14.1M
-
First Round
First Round
(20 Jan 2011)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Private Equity Round - InDex Pharmaceuticals | Valuation |
investors |
|
| Aug, 2018 | Amount | Grant - InDex Pharmaceuticals | Valuation |
investors |
|
| Mar, 2017 | Amount | Grant - InDex Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in InDex Pharmaceuticals
InDex Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SEB, Vinnova and NeoMed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to Swedish companies across sectors.
|
Founded Year | Domain | Location | |
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Founded Year | Domain | Location | |
|
Investments in deep-tech, life sciences, and transformative tech are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by InDex Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - InDex Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Index Pharmaceuticals Comparisons
Competitors of InDex Pharmaceuticals
InDex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Moderna, Incyte, ALX Oncology and MorphoSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Index Pharmaceuticals
Frequently Asked Questions about InDex Pharmaceuticals
When was InDex Pharmaceuticals founded?
InDex Pharmaceuticals was founded in 2000 and raised its 1st funding round 11 years after it was founded.
Where is InDex Pharmaceuticals located?
InDex Pharmaceuticals is headquartered in Stockholm, Sweden.
Is InDex Pharmaceuticals a funded company?
InDex Pharmaceuticals is a funded company, having raised a total of $45.42M across 6 funding rounds to date. The company's 1st funding round was a Grant of $200.56K, raised on Jan 20, 2011.
What does InDex Pharmaceuticals do?
InDex Pharmaceuticals was established in 2000 in Stockholm, Sweden, within the pharmaceuticals sector focused on inflammatory bowel disease. Treatments for ulcerative colitis are developed, including Kappaproct, a DNA-based immunomodulatory sequence medication that delivers targeted anti-inflammatory effects to heal mucosal tissue and alleviate symptoms in severe cases. A diagnostic tool, DiBiCol, is also provided to distinguish ulcerative colitis from Crohns disease among major inflammatory bowel conditions.
Who are the top competitors of InDex Pharmaceuticals?
InDex Pharmaceuticals's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does InDex Pharmaceuticals offer?
InDex Pharmaceuticals offers Investment Services and Insights Platform.
Who are InDex Pharmaceuticals's investors?
InDex Pharmaceuticals has 5 investors. Key investors include SEB, Vinnova, NeoMed, Industrifonden, and EIC Fund.